Arcutis Biotherapeutics, Inc.
ARQT
Rank in Stocks
#4010
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Share Price
$32.29
Last synced: 2026-10-19
Market Cap
$4.06B
Change (1 day)
12.02%
Change (1 year)
54.62%
Country
US
Trade Arcutis Biotherapeutics, Inc. (ARQT)
Category
Healthcare
Number of shares outstanding for Arcutis Biotherapeutics, Inc. (ARQT)
Number of shares outstanding as of June 2026: 130.52M
According to Arcutis Biotherapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 130.52M. At the end of December 2023 the company had 69.31M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Arcutis Biotherapeutics, Inc. (ARQT) from 2017 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 130.52M | 7.91% |
| 2024 | 120.96M | 74.53% |
| 2023 | 69.31M | 25.94% |
| 2022 | 55.03M | 11.39% |
| 2021 | 49.41M | 38.52% |
| 2020 | 35.67M | -6.36% |
| 2019 | 38.09M | 5.11% |
| 2018 | 36.24M | 3,331.44% |
| 2017 | 1.06M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 94.53% |
US
|
|
| 396.00M | 203.40% |
US
|
|
| 478.91M | 266.92% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -52.36% |
NL
|
